Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) to a sell rating in a research note released on Monday.

Separately, Needham & Company LLC reiterated a hold rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, April 11th.

Lexicon Pharmaceuticals Price Performance

LXRX opened at $1.87 on Monday. The stock’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $1.69. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.79. The firm has a market cap of $460.47 million, a price-to-earnings ratio of -2.34 and a beta of 1.27.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. As a group, analysts predict that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Large investors have recently made changes to their positions in the business. Cantor Fitzgerald L. P. bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $25,000. Bank of Montreal Can bought a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at approximately $26,000. TIAA Trust National Association bought a new stake in shares of Lexicon Pharmaceuticals during the third quarter valued at approximately $29,000. Kestra Advisory Services LLC bought a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $33,000. Finally, Principal Securities Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $33,000. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.